An Unlikely Breakthrough
It’s funny how sometimes the most unexpected things can lead to breakthroughs. Take tapeworms, for instance. They’re generally viewed as health nuisances, causing everything from misguided attempts for weight loss to serious neurological issues such as headaches, confusion, and even seizures.
But now, it seems that medication designed to tackle these pesky parasites might open up new avenues for treating a painful condition known as endometriosis, which has long left many women without effective options.
According to Dr. Sheeva Talebian, a board-certified reproductive endocrinologist, the reality is that about 1 in 10 women of reproductive age globally deal with endometriosis. Unfortunately, the condition is often overlooked, with symptoms frequently misdiagnosed or underreported.
However, recent research suggests a promising avenue for treatment. A study published in August in the journal Advanced Healthcare Materials has examined a potential new approach that could directly address the painful lesions associated with endometriosis.
In this research, scientists took niclosamide, a drug approved by the FDA for treating worm infections, and enhanced it with nanotechnology for application in mice. The results were encouraging; the treated mice exhibited reduced inflammation and an inhibition of the spread of lesions, which is significant considering current treatment options mainly offer temporary relief and come with side effects.
Currently, available treatments for endometriosis, such as hormonal therapies, work by suppressing the menstrual cycle to limit lesion growth, while surgeries can remove the lesions or parts of the reproductive system to manage discomfort. However, these methods often accompany side effects, like nausea or mood swings. Plus, there’s always the risk that lesions might regrow post-surgery.
This realization has sparked interest in finding new alternatives. Previous studies had identified a specific group of immune cells linked to the growth of endometrial lesions, which seem to exacerbate painful inflammation. Researchers also noted a distinctive chemical marker in these cells, called a folate receptor, making them a viable target for specific drugs, including niclosamide.
Interestingly, clinicians had been investigating niclosamide for various applications beyond tapeworm infestations, which makes this revelation regarding endometriosis quite fascinating.
The research team collaborated with nanomedicine experts to modify niclosamide, enhancing its solubility in blood by attaching it to a molecule known as a dendrimer. They also included a folate receptor to ensure the medication home in on those rogue immune cells within endometrial tissue.
Anjali Sharma, a specialist in nanomedicine at the University of Michigan, likened the final product to a carshare scenario: “The dendrimer is like the Uber, the folate is like the GPS, and the drug is like the passenger,” she explained, highlighting how the medication is designed to remain inactive until it reaches the targeted cells.
Once inside the affected cells, the drug is released slowly over a two-week period. In mouse studies, a single dose effectively targeted the problematic tissue, significantly alleviating pain and slowing down or stopping the growth of new lesions entirely.
That said, there’s still much to be done before this treatment can be deemed safe for human use, particularly since mice don’t menstruate or experience endometriosis as humans do.
Nonetheless, researchers are optimistic. “There’s a lot of potential in repurposing drugs that have undergone clinical trials to assess their effectiveness for endometriosis,” noted Ioannis Simitsidellis, a postdoctoral researcher from the University of Edinburgh.
Even at this preliminary stage, the team has already received numerous inquiries from individuals interested in participating in future trials. The next steps will involve testing the medication on larger groups and, depending on those results, moving forward to clinical trials with human participants.
